Vaccine therapy may provide an alternative for prostate cancer patients who
se disease no longer responds to hormone therapy. Administration of dendrit
ic cells pulsed with prostate-specific membrane antigen (PSMA) induces cell
ular immune responses against the tumor with virtually no adverse effects.
About 30% of the evaluable patients were identified as partial responders,
based on the National Prostate Cancer Project (NPCP) criteria. In addition,
there was a 50% decrease of serum prostate-specific antigen or resolution
of previously measurable lesions on imaging. Dendritic cell vaccine therapy
may have a synergistic effect, when combined with other therapies.